Management of patients with pulmonary arterial hypertension against of systemic sclerodermia (part 1).
DOI:
https://doi.org/10.26641/2307-0404.2018.3.147959Keywords:
pulmonary arterial hypertension, systemic scleroderma, pharmacological treatment of pulmonary hypertensionAbstract
Pulmonary arterial hypertension (PAH) is a serious condition caused by the damage to the small pulmonary vessels, leading to the increase of pulmonary artery pressure, pulmonary vascular resistance, development of right ventricular failure and death. PAH is one of the actual problems of modern medicine due to low survival rate, rapid disability of the patients and a high cost of treatment. PAH is one of the leading causes of death in systemic scleroderma (SSD). PAH associated with scleroderma is a unique phenotype combining the manifestations of both SSD and PAH, the pathogenetic mechanisms of which modify the clinical picture and the course of these conditions. Timely diagnosis and treatment of PAH show significant effect on survival rates, however, early detection of PAH is still difficult in SSD due to several factors. The main causes are restriction of modern screening methods and polyorganic involvement in SSD. In comparison with other subgroups of PAH the patients with SSD-PAH poorly answer to the specific PAH therapy. SSD-PAH, along with idiopathic pulmonary hypertension (IPAH), belongs to group I of pulmonary hypertension classification and according to modern consensus has a similar pathogenesis and clinical picture, however, differences in the response to therapy in these groups are observed, that indicates the role of other pathobiological mechanisms. Recent investigations explain these differences by such factors as autoimmune and inflammatory responses, more severe vascular remodeling and direct myocardial damage in the SSD. Drug therapy of PH in SSD is similar to that in IPAH and includes prostaglandins, endothelin receptor antagonists, calcium channel blockers, which are prescribed in cases of a positive vasoreactive test, PDE-5 inhibitors. In this literature review we showed traditional and new methods of PAH treatment and their relevance to SSD-PAH in accordance with randomized clinical trials.
References
Mc Laughlin VV, Archer SL, Badesh DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-619. PM ID: 19389575.
McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027
Galie N, Manes A, Negro L. et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J. 2009;30(4):394-403. doi: 10.1093/eurheartj/ehp022
Olsson KM, Delcroix M, Ghofrani HA et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57-65. doi: 10.1161/CIRCULATIONAHA.113.004526
Launay D, Humbert M, Berezne A et al. Clinical characteristics and survival in systemic sclerosis- related pulmonary hypertension associated with interstitial lung disease. Chest. 2011;140(4):1016-24. doi: 10.1378/chest.10-2473
Condliffe R, Kiely DG, Peacock AJ et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179(2):151-7.
Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132(6):425-34.
Zamanian RT, Kudelko KT, SungYK, et al. Current Clinical Management of Pulmonary Arterial Hypertension Circ Res. 2014;115(1):131-47. doi: 10.1161/CIRCRESAHA.115.303827
Duggan ST. Selexipag: A Review in Pulmonary Arterial Hypertension. https://www.ncbi.nlm.nih.gov/pubmed/27988834">Am J Cardiovasc Drugs. 2017;17(1):73-80. doi: 10.1007/s40256-016-0
Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo controlled trial. J Am Coll Cardiol. 2012;39:1496-502.
Montanelli G, Beretta L, Santaniello A, Scorza R. Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin Exp Rheumatol. 2013;31(76):135-9.
Cestelli V, Manfredi A, Sebastiani M et al. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis. https://www.ncbi.nlm.nih.gov/pubmed/27310203">Mod Rheumatol. 2017;27(1):110-4. doi: 10.1080/14397595.2016.1192761
Jing ZC, Parikh K, Pulido T et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624-33.
Saito Y, Nakamura K, Akagi S, et al. Epoprostenol sodium for treatment of pulmonary arterial hypertension. Vasc Health Risk Manag. 2015;11:265-70.
Galiè N, Humbert M, Vachiery JL et al. ESC/ERS guidelines 2015for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119.
Coghlan JG, Denton CP, Grunig E et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340-9.
Ewert R1, Gläser S, Bollmann T, Schäper C. Inhaled iloprost for therapy in pulmonary arterial hypertension. Expert Rev Respir Med. 2011;5(2):145-52. doi: 10.1586/ers.11.14
Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J. 2010;31(15):1898-907.
Badesch DB, McGoon MD, Barst RJ, et al. Long-term survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol. J Rheumatol. 2009;36(10):2244-9.
MathaiSC, Hummers LK. Pulmonary hypertension associated with connective tissue disease. In: Dellaripa PF, Fischer A, Flaherty KR, editors. Pulmonary manifestations of rheumatic diseases: a comprehensive guide. 1st ed.New York: Springer. 2014;139-66.
MathaiSC, Hassoun PM. Pulmonary arterial hypertension in connective tissue diseases. Heart Fail Clin. 2012;8(3):413-25.
Noel ZR. Kido K, Macaulay TE. Selexipag for the treatment of pulmonary arterial hypertension. Am J Health Syst Pharm. 2017;74(15):1135-41. doi: 10.2146/ajhp160798
Tapson VF, Torres F, Kermeen F et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383-90.
Tapson VF, Jing ZC, Xu KF et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952-8.
Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension inFrance: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023-30.
Tapson VF, Gomberg-Maitland M, McLaughlin VV, Benza RL, Widlitz AC, Krichman A. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006;129(3):683-8.
Torres F, Rubin LJ. Treprostinil for the treatment of pulmonary arterial hypertension. Expert Rev Cardiovasc Ther. 2013;11(1):13-25. doi: 10.1586/erc.12.160
Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111(23):3105-11.
Stash JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation. 2011;123(20):2263-73.
MathaiSC, Hummers LK, Champion HC et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009;60(2):569-77.
McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-82.
Bellando-Randone S, Bruni C, Lepri G, et al. The safety of iloprost in systemic sclerosis in a real-life experience. https://www.ncbi.nlm.nih.gov/pubmed/29470737">Clin Rheumatol. 2018;37(5):1249-55. doi: 10.1007/s10067-018-4043-0
Oudiz RJ, Schilz RJ, Barst RJ et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. 2004;126(2):420-7.
Chung L, Farber HW, Benza R et al. Unique predictors of mortality in patients with pulmonary arterial hypertension associated with systemic sclerosis in the REVEAL registry. Chest. 2014;146(6):1494-504.
Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25):34-41.
Galie N, Corris PA, Frost A et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25):60-72.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2018 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
